The Business Research Company’s Metabolic Disorders Drugs Global Market Report 2021 – COVID-19 Impact And Recovery
LONDON, GREATER LONDON, UK, November 17, 2021 /EINPresswire.com/ — Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information. This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases.
Major players covered in the global metabolic disorders drugs industry are Sanofi S.A, Novo Nordisk A/S, AstraZeneca Plc, Johnson & Johnson, Merck & Co.
North America was the largest region in the global metabolic disorders drugs market, accounting for 54% of the market in 2020. Asia Pacific was the second largest region, accounting for 24% of the global metabolic disorders drugs market. Africa was the smallest region in the global metabolic disorders drugs market.
Read More On The Global Metabolic Disorders Drugs Market Report:
The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. These factors are expected to increase the patient pool globally, thereby driving the metabolic disorders drugs market during the forecast period.
The global metabolic disorders drugs market size is expected to grow from $143.16 billion in 2020 to $146.25 billion in 2021 at a compound annual growth rate (CAGR) of 2.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $198.07 billion in 2025 at a CAGR of 8%.
TBRC’s global metabolic disorders drugs market report is segmented by type into anti diabetics drugs, anti-thyroid drugs, others (hyperparathyroidism, hypopituitarism, hypoadrenalism), by distribution channel into hospital pharmacies, retail pharmacies/ drug stores, others, by route of administration into oral, parenteral, others, by drug classification into branded drugs, generic drugs, by mode of purchase into prescription-based drugs, over-the-counter drugs.
Metabolic Disorders Drugs Global Market Report 2021 – By Type (Acne, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), COVID-19 Impact And Recovery is one of a series of new reports from The Business Research Company that provides metabolic disorders drugs market overview, forecast metabolic disorders drugs market size and growth for the whole market, metabolic disorders drugs market segments, and geographies, metabolic disorders drugs market trends, metabolic disorders drugs market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request For A Sample Of The Global Metabolic Disorders Drugs Market Report:
Here Is A List Of Similar Reports By The Business Research Company:
Therapeutic Proteins Global Market Report 2021 – By Product Type (Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), By Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders), By Function (Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics), COVID-19 Impact And Recovery
Biosimilar Growth Hormones Global Market Report 202 – By Route Of Administration (Intravenous, Subcutaneous, Intramuscular, Oral), By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics), COVID-19 Growth And Change
Drugs For Hormonal Replacement Therapy Global Market Report 2021 – By Therapy Type (Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause), By Route of Administration (Oral, Parental), COVID-19 Impact and Recovery
Interested to know more about The Business Research Company?
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
Or get a quick glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Source: EIN Presswire